Biotech pharma

TareBio

Website
Founded 2026Origin source ↗Checked 2026-09-15

Overview

Our platform develops personalized or population-level vaccines for any disease in weeks by changing only one input: the immune imprint. Instead of trying to predict which antigens might work, we read out immune cells already fighting the disease in the body and reverse-engineer antigens that activate them. We've already run our platform end-to-end and created a vaccine that cured cancer in mice.

Company description As recorded 2026-11-08

Founders & team

Eta Atolia

Founder/CEO

Founder & CEO, TareBio (YC S26). MD-PhD from UCLA-Caltech, where she built a novel platform that develops vaccines for any cancer or infection in weeks, funded by the Gates Foundation. BS in Biology from MIT. Conducted research at the Koch Institute, Harvard Medical School, and the Weizmann. Select Awards: UCLA MD-PhD Merit Scholar, UCLA TDG Senior Fellow, MIT iGEM Gold Medal, MIT IDEAs winner, MIT Dean Advisory Group, WhiteHouse Science Fair, Bessie Lawrence Scholar, Intel STS Finalist

Founder profile As recorded 2026-09-15
1team members reported
Source-reported As recorded 2026-09-15

Founded 2026 · Source

News & product activity

Sources & observations

Y Combinator

Profile depthverified profile
Website observationwebsite reachable
Last website check2026-11-11
Location · source statedSan Francisco, CA, USA
Pricing evidenceNo pricing page confirmed
Maturity: Not assessed · 3 of 6 areas documented

Source-based assessment · automated evidence rules

The retained text does not establish product availability or customer use.

Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.

Stage definitions
independent websitesource corroborationreachable websitedescriptive evidenceclassified market and modelsourced peoplesourced founding year